Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation

T. R. Srinivas, J. D. Schold, Giselle Guerra, A. Eagan, C. M. Bucci, H. U. Meier-Kriesche

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

We evaluated outcomes with the sirolimus (SRL) and mycophenolate mofetil (MMF) combination regimen (SRL/MMF) in solitary kidney transplant recipients transplanted between 2000 and 2005 reported to the Scientific Registry of Renal Transplant Recipients. Three-and-a-half percent received SRL/MMF (n = 2040). Six-month acute rejection rates were higher with SRL/MMF (SRL/MMF: 16.0% vs. other regimens: 11.2%, p < 0.001). Overall graft survival was significantly lower on SRL/MMF. SRL/MMF was associated with twice the hazard for graft loss (AHR = 2.0, 95% C.I., 1.8, 2.2) relative to TAC/MMF, also consistent in both living donor transplants (AHR = 2.4, 95% C.I., 1.9, 2.9) and expanded criteria donor transplants (AHR = 2.1, 95% C.I., 1.7-2.5). Among deceased donor transplants, DGF rates were higher in the SRL/MMF cohort (47% vs. 27%, p < 0.001). However, adjusted graft survival was also significantly inferior with SRL/MMF in DGF-free patients (AHR = 1.9, 95% C.I., 1.6-2.3). In analyses restricted to patients who remained on the discharge regimen at 6 months posttransplant, conditional graft survival in deceased donor transplants was significantly lower with SRL/MMF compared to patients on TAC/MMF or CsA/MMF regimens at 5 years posttransplant (64%, 78%, 78%, respectively, p = 0.001) and across all patient subgroups. In conclusion, SRL/MMF is associated with inferior renal transplant outcomes compared with other commonly used regimens.

Original languageEnglish
Pages (from-to)586-594
Number of pages9
JournalAmerican Journal of Transplantation
Volume7
Issue number3
DOIs
StatePublished - Mar 1 2007
Externally publishedYes

Fingerprint

Mycophenolic Acid
Sirolimus
Immunosuppressive Agents
Kidney Transplantation
Graft Survival
Tissue Donors
Transplants
Kidney
Living Donors

Keywords

  • Calcium inhibitor
  • Cyclosporin
  • M-TOR inhibitor
  • Mycophenolate mofetil
  • Rapamycin
  • Tacrolimus

ASJC Scopus subject areas

  • Immunology

Cite this

Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. / Srinivas, T. R.; Schold, J. D.; Guerra, Giselle; Eagan, A.; Bucci, C. M.; Meier-Kriesche, H. U.

In: American Journal of Transplantation, Vol. 7, No. 3, 01.03.2007, p. 586-594.

Research output: Contribution to journalArticle

Srinivas, T. R. ; Schold, J. D. ; Guerra, Giselle ; Eagan, A. ; Bucci, C. M. ; Meier-Kriesche, H. U. / Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. In: American Journal of Transplantation. 2007 ; Vol. 7, No. 3. pp. 586-594.
@article{98b2fb6e8b8c40b183d5edfc75491fd0,
title = "Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation",
abstract = "We evaluated outcomes with the sirolimus (SRL) and mycophenolate mofetil (MMF) combination regimen (SRL/MMF) in solitary kidney transplant recipients transplanted between 2000 and 2005 reported to the Scientific Registry of Renal Transplant Recipients. Three-and-a-half percent received SRL/MMF (n = 2040). Six-month acute rejection rates were higher with SRL/MMF (SRL/MMF: 16.0{\%} vs. other regimens: 11.2{\%}, p < 0.001). Overall graft survival was significantly lower on SRL/MMF. SRL/MMF was associated with twice the hazard for graft loss (AHR = 2.0, 95{\%} C.I., 1.8, 2.2) relative to TAC/MMF, also consistent in both living donor transplants (AHR = 2.4, 95{\%} C.I., 1.9, 2.9) and expanded criteria donor transplants (AHR = 2.1, 95{\%} C.I., 1.7-2.5). Among deceased donor transplants, DGF rates were higher in the SRL/MMF cohort (47{\%} vs. 27{\%}, p < 0.001). However, adjusted graft survival was also significantly inferior with SRL/MMF in DGF-free patients (AHR = 1.9, 95{\%} C.I., 1.6-2.3). In analyses restricted to patients who remained on the discharge regimen at 6 months posttransplant, conditional graft survival in deceased donor transplants was significantly lower with SRL/MMF compared to patients on TAC/MMF or CsA/MMF regimens at 5 years posttransplant (64{\%}, 78{\%}, 78{\%}, respectively, p = 0.001) and across all patient subgroups. In conclusion, SRL/MMF is associated with inferior renal transplant outcomes compared with other commonly used regimens.",
keywords = "Calcium inhibitor, Cyclosporin, M-TOR inhibitor, Mycophenolate mofetil, Rapamycin, Tacrolimus",
author = "Srinivas, {T. R.} and Schold, {J. D.} and Giselle Guerra and A. Eagan and Bucci, {C. M.} and Meier-Kriesche, {H. U.}",
year = "2007",
month = "3",
day = "1",
doi = "10.1111/j.1600-6143.2006.01658.x",
language = "English",
volume = "7",
pages = "586--594",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation

AU - Srinivas, T. R.

AU - Schold, J. D.

AU - Guerra, Giselle

AU - Eagan, A.

AU - Bucci, C. M.

AU - Meier-Kriesche, H. U.

PY - 2007/3/1

Y1 - 2007/3/1

N2 - We evaluated outcomes with the sirolimus (SRL) and mycophenolate mofetil (MMF) combination regimen (SRL/MMF) in solitary kidney transplant recipients transplanted between 2000 and 2005 reported to the Scientific Registry of Renal Transplant Recipients. Three-and-a-half percent received SRL/MMF (n = 2040). Six-month acute rejection rates were higher with SRL/MMF (SRL/MMF: 16.0% vs. other regimens: 11.2%, p < 0.001). Overall graft survival was significantly lower on SRL/MMF. SRL/MMF was associated with twice the hazard for graft loss (AHR = 2.0, 95% C.I., 1.8, 2.2) relative to TAC/MMF, also consistent in both living donor transplants (AHR = 2.4, 95% C.I., 1.9, 2.9) and expanded criteria donor transplants (AHR = 2.1, 95% C.I., 1.7-2.5). Among deceased donor transplants, DGF rates were higher in the SRL/MMF cohort (47% vs. 27%, p < 0.001). However, adjusted graft survival was also significantly inferior with SRL/MMF in DGF-free patients (AHR = 1.9, 95% C.I., 1.6-2.3). In analyses restricted to patients who remained on the discharge regimen at 6 months posttransplant, conditional graft survival in deceased donor transplants was significantly lower with SRL/MMF compared to patients on TAC/MMF or CsA/MMF regimens at 5 years posttransplant (64%, 78%, 78%, respectively, p = 0.001) and across all patient subgroups. In conclusion, SRL/MMF is associated with inferior renal transplant outcomes compared with other commonly used regimens.

AB - We evaluated outcomes with the sirolimus (SRL) and mycophenolate mofetil (MMF) combination regimen (SRL/MMF) in solitary kidney transplant recipients transplanted between 2000 and 2005 reported to the Scientific Registry of Renal Transplant Recipients. Three-and-a-half percent received SRL/MMF (n = 2040). Six-month acute rejection rates were higher with SRL/MMF (SRL/MMF: 16.0% vs. other regimens: 11.2%, p < 0.001). Overall graft survival was significantly lower on SRL/MMF. SRL/MMF was associated with twice the hazard for graft loss (AHR = 2.0, 95% C.I., 1.8, 2.2) relative to TAC/MMF, also consistent in both living donor transplants (AHR = 2.4, 95% C.I., 1.9, 2.9) and expanded criteria donor transplants (AHR = 2.1, 95% C.I., 1.7-2.5). Among deceased donor transplants, DGF rates were higher in the SRL/MMF cohort (47% vs. 27%, p < 0.001). However, adjusted graft survival was also significantly inferior with SRL/MMF in DGF-free patients (AHR = 1.9, 95% C.I., 1.6-2.3). In analyses restricted to patients who remained on the discharge regimen at 6 months posttransplant, conditional graft survival in deceased donor transplants was significantly lower with SRL/MMF compared to patients on TAC/MMF or CsA/MMF regimens at 5 years posttransplant (64%, 78%, 78%, respectively, p = 0.001) and across all patient subgroups. In conclusion, SRL/MMF is associated with inferior renal transplant outcomes compared with other commonly used regimens.

KW - Calcium inhibitor

KW - Cyclosporin

KW - M-TOR inhibitor

KW - Mycophenolate mofetil

KW - Rapamycin

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=33847717932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847717932&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2006.01658.x

DO - 10.1111/j.1600-6143.2006.01658.x

M3 - Article

VL - 7

SP - 586

EP - 594

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 3

ER -